Matthew Reynolds to Health Care Costs
This is a "connection" page, showing publications Matthew Reynolds has written about Health Care Costs.
Connection Strength
4.980
-
Sutton BS, Bermingham SL, Diamantopoulos A, Rosemas SC, Tsintzos SI, Xia Y, Reynolds MR. Economic value of insertable cardiac monitors in unexplained syncope in the United States. Open Heart. 2021 02; 8(1).
Score: 0.608
-
Griffiths RI, Amorosi SL, Jacobsen CM, McBee PJ, Menzin J, Reynolds MR. Costs and complications associated with transvenous lead reoperation in cardiac implantable electronic devices. J Cardiovasc Electrophysiol. 2020 02; 31(2):503-511.
Score: 0.566
-
Turakhia MP, Zweibel S, Swain AL, Mollenkopf SA, Reynolds MR. Healthcare Utilization and Expenditures Associated With Appropriate and Inappropriate Implantable Defibrillator Shocks. Circ Cardiovasc Qual Outcomes. 2017 02; 10(2).
Score: 0.461
-
Reynolds MR, Baron SJ, Cohen DJ. Economic Implications of Transcatheter Aortic Valve Replacement in Patients at Intermediate Surgical Risk. Circulation. 2016 11 08; 134(19):1416-1418.
Score: 0.453
-
Majithia A, Reynolds MR. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: rarely a good value. Europace. 2015 Jan; 17(1):5-6.
Score: 0.399
-
Reynolds MR, Apruzzese P, Galper BZ, Murphy TP, Hirsch AT, Cutlip DE, Mohler ER, Regensteiner JG, Cohen DJ. Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial. J Am Heart Assoc. 2014 Nov 11; 3(6):e001233.
Score: 0.395
-
Reynolds MR, Cohen DJ. The cost-effectiveness of transcatheter aortic valve replacement for nonsurgical candidates: revisionist history or the final word? Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):376-8.
Score: 0.360
-
Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala JM, O'Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation. 2012 Mar 06; 125(9):1102-9.
Score: 0.326
-
Ladapo JA, David G, Gunnarsson CL, Hao SC, White SA, March JL, Reynolds MR. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation. J Cardiovasc Electrophysiol. 2012 Jan; 23(1):1-8.
Score: 0.314
-
Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol. 2008 Dec 16; 52(25):2119-26.
Score: 0.262
-
Reynolds MR, Pinto DS, Shi C, Walczak J, Berezin R, Holmes DR, Cohen DJ. Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. Am Heart J. 2007 Dec; 154(6):1221-7.
Score: 0.240
-
Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007 Jun; 18(6):628-33.
Score: 0.234
-
Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz Angulo ME, Diener HC. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int J Stroke. 2016 Apr; 11(3):302-12.
Score: 0.107
-
Voigt J, Sasha John M, Taylor A, Krucoff M, Reynolds MR, Michael Gibson C. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol. 2014 May; 37(5):312-21.
Score: 0.095
-
Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006 Dec; 152(6):1097-103.
Score: 0.057
-
Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MJ, Brown DL, Russo MJ, Smith CR, Webb J, Miller C, Leon MB, Cohen DJ. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019 02 12; 139(7):877-888.
Score: 0.033
-
Osnabrugge RL, Kappetein AP, Reynolds MR, Cohen DJ. Cost-effectiveness of transcatheter valvular interventions: economic challenges. EuroIntervention. 2013 Sep 10; 9 Suppl:S48-54.
Score: 0.023
-
Amin AP, Reynolds MR, Lei Y, Magnuson EA, Vilain K, Durtschi AJ, Simonton CA, Stone GW, Cohen DJ. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). Am J Cardiol. 2012 Sep 15; 110(6):765-70.
Score: 0.021
-
Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008 Nov 25; 52(22):1758-68.
Score: 0.016
-
Zimetbaum P, Reynolds MR, Ho KK, Gaziano T, McDonald MJ, McClennen S, Berezin R, Josephson ME, Cohen DJ. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol. 2003 Sep 15; 92(6):677-81.
Score: 0.011